AwesomeCapital

Eagle Pharma beats Q2 consensus

Eagle Pharmaceuticals (EGRX) Q2 results: Revenues: $56.7M (-4.4%); Product sales: $29.4M (+27.8%); Royalty revenue: $27.3M (-24.8%).

BELRAPZO sales were $15.4M, +90.1% Y/Y

RYANODEX sales were $2.9M, down 59.7% Y/Y.

Net Income: $6.7M (+148.1%); EPS: $0.48 (+182.4%); Non-GAAP Net Income: $11.8M (-19.7%); Non-GAAP EPS: $0.84 (-11.6%); CF Ops: $48.6M.

Previously: Eagle Pharmaceuticals EPS beats by $0.01, beats on revenue(Aug. 8)

https://seekingalpha.com/news/3489359-eagle-pharma-beats-q2-consensus

Achillion Pharmaceuticals EPS in-line

Achillion Pharmaceuticals (NASDAQ:ACHN): Q2 GAAP EPS of -$0.14 in-line.

Cash, cash equivalents and marketable securities of $241.3M

Press Release

https://seekingalpha.com/news/3489396-achillion-pharmaceuticals-eps-line

Bayer to acquire remaining stake in BlueRock Therapeutics for up to $600M

Bayer (OTCPK:BAYRY) has agreed to acquire the 59.2% of privately held BlueRock Therapeutics that it does not own for $240M in upfront cash plus up to $360M contingent on the achievement of certain development milestones. The transaction should close this quarter.

The company acquired 40.8% of the cell therapy developer when it established BlueRock with Versant Ventures in 2016 with $225M in Series A financing. Bayer will own full rights to its CELL+GENE platform.

BlueRock’s lead program is in Parkinson’s disease.

https://seekingalpha.com/news/3489386-bayer-acquire-remaining-stake-bluerock-therapeutics-600m